About: CHEST Reviews: Addressing reduced laboratory-based pulmonary function testing during a pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CHEST Reviews: Addressing reduced laboratory-based pulmonary function testing during a pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	CHEST Reviews: Addressing reduced laboratory-based pulmonary function testing during a pandemic
Creator	To, Teresa Goldstein, Roger Gershon, Andrea Michael, St Bch, M Chow, Chung-Wai Chapman, Kenneth Gupta, Samir Tarlo, Susan Facp, Frcpc Fers, Fccp Frcpc, Bch Frcpc, Mbbs Kouri, Andrew Ryan, Clodagh To Phd, Teresa Yadollahi Phd, Azadeh Yadollahi, Azadeh
source	Elsevier; Medline; PMC
abstract	Abstract To reduce the spread of SARS-CoV-2, many pulmonary function testing (PFT) laboratories have been closed or have significantly reduced their testing capacity. As these mitigation strategies may be necessary for the next 6-18 months to prevent recurrent peaks in disease prevalence, fewer objective measurements of lung function will alter the diagnosis and care of patients with chronic respiratory diseases. PFTs, which include spirometry, lung volumes, and diffusion capacity measurement, are essential to the diagnosis and management of patients with asthma, COPD, and other chronic lung conditions. Both traditional and innovative alternatives to conventional testing must now be explored. These may include peak expiratory flow devices, electronic portable spirometers, portable exhaled nitric oxide measurement, airwave oscillometry devices, as well as novel digital health tools such as smartphone microphone spirometers, and mobile health technologies along integration of machine learning approaches. The adoption of some novel approaches may not merely replace but could improve existing management strategies and alter common diagnostic paradigms. With these options come important technical, privacy, ethical, financial, and medicolegal barriers that must be addressed. However, the COVID-19 pandemic also presents a unique opportunity to augment conventional testing by including innovative and emerging approaches to measuring lung function remotely in patients with respiratory disease. The benefits of such an approach have the potential to enhance respiratory care and empower patient self-management well beyond the current global pandemic.
has issue date	2020-07-08(xsd:dateTime)
bibo:doi	10.1016/j.chest.2020.06.065
bibo:pmid	32652095
has license	els-covid
sha1sum (hex)	6a9014afff77068b261747f0f1cd37c12fa29f43
schema:url	https://doi.org/10.1016/j.chest.2020.06.065
resource representing a document's title	CHEST Reviews: Addressing reduced laboratory-based pulmonary function testing during a pandemic
has PubMed Central identifier	PMC7345485
has PubMed identifier	32652095
schema:publication	Chest
resource representing a document's body	covid:6a9014afff77068b261747f0f1cd37c12fa29f43#body_text
is schema:about of	named entity 'pandemic' named entity 'pulmonary function testing' named entity 'lung volume' named entity 'long-term' named entity 'diurnal' named entity 'COPD' named entity 'mHealth' named entity 'COPD' named entity 'PFTs' named entity 'spirometry' named entity 'viral testing' named entity 'Lung Function' named entity 'spirometry' named entity 'personal protective equipment' named entity 'pulmonary function testing' named entity 'mHealth' named entity 'PFTs' named entity 'laboratory testing' named entity 'asthma' named entity 'chronic respiratory diseases' named entity 'machine learning' named entity 'COPD' named entity 'laboratory testing' named entity 'spirometry' named entity 'machine learning' named entity 'PFT' named entity 'PEF' named entity 'triaging' named entity 'higher risk' named entity 'spirometers' named entity 'therapeutic interventions' named entity 'COPD' named entity 'chronic respiratory diseases' named entity 'chronic respiratory diseases' named entity 'exhaled nitric oxide' named entity 'COPD' named entity 'PFT' named entity 'asthma' named entity 'flowmeter' named entity 'respiratory diseases' named entity 'COVID-19' named entity 'COPD' named entity 'airway obstruction' named entity 'prognostication' named entity 'asthma' named entity 'PFTs' named entity 'inflammation' named entity 'spirometers' named entity 'healthcare services' named entity 'mHealth' named entity 'mHealth' named entity 'asthma' named entity 'respiratory symptoms' named entity 'lung function' named entity 'COPD' named entity 'lung function' named entity 'asthma' named entity 'albuterol' named entity 'cystic fibrosis' named entity 'asthma' named entity 'follow-up' named entity 'PFTs' named entity 'overdiagnosis' named entity 'FEV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software